Zachary F. Zimmerman

Learn More
OBJECTIVE To evaluate the cost-effectiveness of blinatumomab (Blincyto) vs standard of care (SOC) chemotherapy in adults with relapsed or refractory (R/R) Philadelphia-chromosome-negative (Ph-)(More)
  • 1